Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)

AIMS: Little is known about the impact of sodium glucose co‐transporter 2 (SGLT2) inhibitors on cardiac biomarkers, such as natriuretic peptides, in type 2 diabetes (T2D) patients with concomitant chronic heart failure (CHF). We compared the effect of canagliflozin with glimepiride, based on changes...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Atsushi, Hisauchi, Itaru, Taguchi, Isao, Sezai, Akira, Toyoda, Shigeru, Tomiyama, Hirofumi, Sata, Masataka, Ueda, Shinichiro, Oyama, Jun‐ichi, Kitakaze, Masafumi, Murohara, Toyoaki, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373938/
https://www.ncbi.nlm.nih.gov/pubmed/32349193
http://dx.doi.org/10.1002/ehf2.12707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373938/
https://www.ncbi.nlm.nih.gov/pubmed/32349193
http://dx.doi.org/10.1002/ehf2.12707

Ejemplares similares